Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group
- PMID: 23130127
- PMCID: PMC3487365
- DOI: 10.1161/JAHA.111.000554
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group
Keywords: genetic polymorphisms; genetics; pharmacogenetics; pharmacogenetics anticoagulants; pharmacogenetics cholesterol.
Similar articles
-
Pharmacogenomics guidelines: Current status and future development.Clin Exp Pharmacol Physiol. 2019 Aug;46(8):689-693. doi: 10.1111/1440-1681.13097. Epub 2019 May 16. Clin Exp Pharmacol Physiol. 2019. PMID: 31009088 Review.
-
Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).Therapie. 2017 Apr;72(2):257-267. doi: 10.1016/j.therap.2016.09.017. Epub 2017 Jan 30. Therapie. 2017. PMID: 28237404 Review.
-
Clinical Review of the Pharmacogenomics of Direct Oral Anticoagulants.Cardiovasc Drugs Ther. 2018 Feb;32(1):121-126. doi: 10.1007/s10557-018-6774-1. Cardiovasc Drugs Ther. 2018. PMID: 29435777 Review.
-
Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.Oncotarget. 2018 Jun 26;9(49):29238-29258. doi: 10.18632/oncotarget.25579. eCollection 2018 Jun 26. Oncotarget. 2018. PMID: 30018749 Free PMC article. Review.
-
Cardiovascular pharmacogenomics: current status, future prospects.J Cardiovasc Pharmacol Ther. 2003 Mar;8(1):71-83. doi: 10.1177/107424840300800i110. J Cardiovasc Pharmacol Ther. 2003. PMID: 12652332 Review.
Cited by
-
Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?J Am Heart Assoc. 2016 Mar 28;5(3):e003440. doi: 10.1161/JAHA.116.003440. J Am Heart Assoc. 2016. PMID: 27021567 Free PMC article. No abstract available.
-
A Framework for Prioritizing Research Investments in Precision Medicine.Med Decis Making. 2016 Jul;36(5):567-80. doi: 10.1177/0272989X15610780. Epub 2015 Oct 26. Med Decis Making. 2016. PMID: 26502985 Free PMC article.
-
CgGCS, Encoding a Glucosylceramide Synthase, Is Required for Growth, Conidiation and Pathogenicity in Colletotrichum gloeosporioides.Front Microbiol. 2019 May 21;10:1016. doi: 10.3389/fmicb.2019.01016. eCollection 2019. Front Microbiol. 2019. PMID: 31164871 Free PMC article.
References
-
- Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331 - PMC - PubMed
-
- Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-4112 - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources